Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer

(Neutral)

(Very Positive)

Rhea-AI Summary

Integra LifeSciences (Nasdaq:IART) appointed Topaz Kirlew as corporate vice president and chief regulatory officer, leading global regulatory affairs and strategy.

She previously served as interim regulatory leader, overseeing compliance, submissions, and risk mitigation, and brings over 35 years of healthcare and medical technology experience across regulatory, quality, operations, clinical, and laboratory roles.

News Market Reaction – IART

+0.89%

+0.89% News Effect

On the day this news was published, IART gained 0.89%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Elevating a seasoned executive with more than 35 years healthcare experience to chief regulatory off...

Analysis

Elevating a seasoned executive with more than 35 years healthcare experience to chief regulatory officer extends Integra’s recent leadership reshaping. With an effective S-3 shelf in place, investors may watch how regulatory execution and any future capital raises intersect.

Key Figures

Industry experience: more than 35 years Equity plan increase: 3,550,000 shares Paradigm ownership: 4,012,698 shares (5.16%) +5 more

8 metrics

Industry experience more than 35 years Healthcare and medical technology experience for new chief regulatory officer

Equity plan increase 3,550,000 shares Additional common shares approved for equity awards at 2026 Annual Meeting

Paradigm ownership 4,012,698 shares (5.16%) Schedule 13G passive stake as of 03/31/2026

Shares issued 77,886,634 shares Common stock issued as of December 31, 2025

Treasury stock 14,398,724 shares Common shares designated as treasury stock as of December 31, 2025

Reference share price $11.59 IART Nasdaq closing price on February 25, 2026 cited in S-3ASR

McBreen RSU grant 31,909 RSUs Equity award to EVP & Chief Commercial Officer on Form 4

Essig option grant 705,468 options at $15.67 Non-qualified stock options granted to President and CEO

Historical Context

5 past events · Latest: Jun 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 23	Executive appointments	Positive	+0.5%	New senior commercial leadership roles announced to support long-term growth.
Jun 15	Conference appearance	Neutral	-1.7%	Company presentation scheduled at the 2026 Truist Securities MedTech Conference.
Jun 02	Conference appearance	Neutral	+0.0%	CFO presentation announced for the 2026 Jefferies Global Healthcare Conference.
May 08	Conference appearance	Neutral	+2.6%	CFO scheduled to present at the BofA Securities 2026 Health Care Conference.
May 05	Leadership transition	Positive	+24.1%	Stuart Essig appointed president and CEO in a permanent leadership transition.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent IART headlines around leadership and investor events have generally seen modest stock reactions, with a notably stronger move on the prior CEO leadership transition.

Key Terms

regulatory affairs, regulatory compliance, clinical laboratory scientist

3 terms

regulatory affairs regulatory

"Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy"

Regulatory affairs is the team and processes that secure and maintain government approvals, permits, and ongoing compliance for a company’s products, such as drugs, medical devices, or financial offerings. Think of them as the navigator and permit office that prepares submission paperwork, answers regulator questions, and monitors safety and labeling after launch. Their work matters to investors because regulatory timing, costs, and approval risk directly affect a product’s ability to reach markets and generate revenue.

regulatory compliance regulatory

"she provided oversight of regulatory compliance, managed active submissions"

Regulatory compliance is the process of ensuring that a company follows all applicable laws, rules, and standards set by government authorities or industry bodies. It is important to investors because it helps prevent legal penalties, financial losses, and reputational damage, contributing to the overall stability and trustworthiness of a business. Think of it as following the rules of a game to play fairly and avoid penalties.

clinical laboratory scientist medical

"She began her career as a clinical laboratory scientist, serving at leading healthcare institutions"

A clinical laboratory scientist is a trained professional who performs and interprets medical tests on blood, tissue and other samples to detect disease, measure health markers and ensure test accuracy — think of them as the diagnostic 'detectives' and quality-control experts inside a lab. Investors care because their work determines how reliable and fast a company’s testing services are, affects regulatory compliance and operating costs, and therefore influences patient trust, revenue, and risk exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/02/2026 - 08:30 AM

Kirlew will lead Integra’s global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution.

PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide.

Kirlew served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed active submissions, and led risk mitigation efforts across the organization.

"Topaz brings deep regulatory experience, sound judgment, and a practical approach to helping the business move forward the right way," said Stuart Essig, chairman and chief executive officer of Integra LifeSciences. "She has earned the confidence of the leadership team, and I am pleased to have her in this role as we continue to strengthen our regulatory capabilities and advance our mission of restoring patients' lives."

Since joining Integra in 2021, Kirlew has played a key role in building the company's regulatory capabilities and advancing key business priorities. She brings more than 35 years of healthcare and medical technology industry experience spanning regulatory affairs, quality, operations, and clinical functions.

Prior to joining Integra, Kirlew held positions of increasing responsibility at several healthcare and medical technology organizations, including Danaher Corporation, Apyx Medical, Bio-Tissue, and the University of Miami's Diabetes Research Institute. She began her career as a clinical laboratory scientist, serving at leading healthcare institutions including the National Institutes of Health, Georgetown University Hospital, and the University of Maryland Medical Center.

Kirlew earned a bachelor’s degree in clinical laboratory science from Florida International University and holds a master's degree and a doctorate in business administration from Nova Southeastern University's School of Business and Entrepreneurship.

About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.

Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com

Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1a23fae4-98d6-4910-9b3a-5172804e1e1c

FAQ

What role was Topaz Kirlew appointed to at Integra LifeSciences (NASDAQ:IART) on July 2, 2026?

Topaz Kirlew was appointed corporate vice president and chief regulatory officer at Integra LifeSciences. According to Integra, she will lead the global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide for the company.

What are the responsibilities of Integra LifeSciences’ new chief regulatory officer for IART?

The chief regulatory officer will lead Integra’s global regulatory affairs organization and oversee regulatory strategy, compliance, and submissions. According to Integra, the role also includes guiding regulatory transformation initiatives as the company continues strengthening quality, compliance, and execution across its global operations.

What experience does Topaz Kirlew bring to Integra LifeSciences as chief regulatory officer (IART)?

Topaz Kirlew brings more than 35 years of healthcare and medical technology industry experience. According to Integra, her background spans regulatory affairs, quality, operations, and clinical functions, including roles at Danaher, Apyx Medical, Bio-Tissue, and leading healthcare and research institutions.

How did Topaz Kirlew contribute to Integra LifeSciences before becoming chief regulatory officer for IART?

Before her appointment, Kirlew served as Integra’s interim regulatory leader. According to Integra, she oversaw regulatory compliance, managed active submissions, led risk mitigation efforts, and played a key role in building the company’s regulatory capabilities since joining the organization in 2021.

What is Topaz Kirlew’s educational background relevant to her new role at Integra LifeSciences (IART)?

Topaz Kirlew holds a bachelor’s degree in clinical laboratory science and advanced business degrees. According to Integra, she earned her bachelor’s from Florida International University and a master’s and doctorate in business administration from Nova Southeastern University’s School of Business and Entrepreneurship.